Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
| Autor: | Sibel İnan, Rahmi Duman, Reşat Duman, Neriman Efe, Onur Polat, Muberra Akdogan, Elif Ertan, Mustafa Doğan |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Intraocular pressure medicine.medical_specialty Visual acuity genetic structures Recombinant Fusion Proteins Visual Acuity Angiogenesis Inhibitors Fundus (eye) Ranibizumab/therapeutic use Angiogenesis inhibitors/therapeutic use Macular Degeneration Age related Ophthalmology Ranibizumab medicine Humans Aflibercept Aged Retrospective Studies Aged 80 and over Intravitreal injections business.industry Macular degeneration Retina/pathology Retrospective cohort study General Medicine RE1-994 medicine.disease eye diseases Receptors Vascular Endothelial Growth Factor Treatment Outcome Child Preschool Intravitreal Injections Female sense organs medicine.symptom business Tomography Optical Coherence medicine.drug |
| Zdroj: | Arquivos Brasileiros de Oftalmologia, Vol 84, Iss 3, Pp 225-229 (2021) Arquivos Brasileiros de Oftalmologia v.84 n.3 2021 Arquivos brasileiros de oftalmologia Conselho Brasileiro de Oftalmologia (CBO) instacron:CBO |
| ISSN: | 1678-2925 |
| Popis: | Purpose: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. Methods: This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections followed by a prore nata dosing regimen and after 30 months of treatment. Best corrected visual acuity, biomicroscopic examination, intraocular pressure, fundus examination, and central macular thickness were recorded at the start of treatment, before the transition to intravitreal aflibercept treatment, and at 6, 12, 18, 24, and 30 months of intravitreal aflibercept treatment. Results: A total of 33 eyes met the inclusion criteria. The median age of the patients was 73.57 ± 7.98 years, and 21 (61.8%) patients were males and 12 (35.3%) were females. Before the transition, the patients received a mean of 16.8 ± 8.8 ranibizumab injections (range 6-38).After the transition to intravitreal aflibercept treatment, the mean number of aflibercept injections was 9.09 ± 3.94. No significant differences were observed in best corrected visual acuity after the aflibercept switch in any of the months. The central macular thickness was significantly decreased at 6, 12, 18, and 30 months (p=0.01, p=0.03, p=0.05, p=0.05, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|